Editorial
doi: 10.1056/NEJMe2031382.
Epub 2020 Oct 23.
Finerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease
Affiliations
- PMID: 33095527
- DOI: 10.1056/NEJMe2031382
Item in Clipboard
Editorial
Finerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease
N Engl J Med.
.
No abstract available
Comment on
-
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Clinical Trial.
Similar articles
-
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218. Eur J Heart Fail. 2015. PMID: 25678098 Clinical Trial.
-
Finerenone (Kerendia) for chronic kidney disease.Med Lett Drugs Ther. 2021 Aug 23;63(1631):131-132. Med Lett Drugs Ther. 2021. PMID: 34544101 Review. No abstract available.
-
[Finerenone in patients with chronic kidney disease and type 2 diabetes mellitus].Internist (Berl). 2021 May;62(5):577-580. doi: 10.1007/s00108-021-01028-7. Epub 2021 Apr 20. Internist (Berl). 2021. PMID: 33877367 German. No abstract available.
-
Letter to the Editor: Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection.Curr Probl Cardiol. 2024 Jan;49(1 Pt B):102067. doi: 10.1016/j.cpcardiol.2023.102067. Epub 2023 Sep 9. Curr Probl Cardiol. 2024. PMID: 37678423 Review. No abstract available.
-
Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?Eur J Clin Invest. 2023 Feb;53(2):e13864. doi: 10.1111/eci.13864. Epub 2022 Sep 6. Eur J Clin Invest. 2023. PMID: 36038512 No abstract available.
Cited by
-
Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Front Pharmacol. 2022 Feb 7;13:819327. doi: 10.3389/fphar.2022.819327. eCollection 2022. Front Pharmacol. 2022. PMID: 35197856 Free PMC article. Review.
-
Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial.Clin Kidney J. 2023 Sep 26;17(1):sfad249. doi: 10.1093/ckj/sfad249. eCollection 2024 Jan. Clin Kidney J. 2023. PMID: 38186886 Free PMC article.
-
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.Clin Pharmacokinet. 2022 Mar;61(3):439-450. doi: 10.1007/s40262-021-01082-2. Epub 2021 Nov 13. Clin Pharmacokinet. 2022. PMID: 34773606 Free PMC article. Clinical Trial.
-
Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.Front Pharmacol. 2022 Jun 16;13:896947. doi: 10.3389/fphar.2022.896947. eCollection 2022. Front Pharmacol. 2022. PMID: 35784710 Free PMC article.
-
Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes.Diabetol Metab Syndr. 2024 Nov 24;16(1):283. doi: 10.1186/s13098-024-01525-3. Diabetol Metab Syndr. 2024. PMID: 39582036 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
